Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer

Serum from one hundred and ten breast cancer patients and thirty healthy female volunteers, were prospectively collected and evaluated for serum levels of Shh and IL-6 using human Shh and IL-6 specific enzyme-linked immunoassays. All patients were regularly monitored for event free survival (EFS) an...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Scientific reports Ročník 7; číslo 1; s. 1796 - 12
Hlavní autori:	Noman, A. S., Uddin, M., Chowdhury, A. A., Nayeem, M. J., Raihan, Z., Rashid, M. I., Azad, A. K., Rahman, M. L., Barua, D., Sultana, A., Shirin, A., Ferdous, J., Parag, R. R., Rahman, S. M., Mahmud, M. R., Jerin, C. S., Jahan, N., Siddiqua, A., Ara, T., Sabur, E. B., Alam, S. S., Baidya, S., Akther, S., Rahman, M. Z., Banu, T., Murugan, A. K., Sabri, S., Islam, S. M. S., Karakas, B., Aboussekhra, A., Yeger, H., Farhat, W. A., Islam, S. S.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 11.05.2017 Nature Publishing Group Nature Portfolio
Predmet:	13 13/21 13/31 14 14/1 14/105 14/19 38 38/91 631/67/1347 631/67/1857 Biomarkers Biomarkers, Tumor Bone Neoplasms - secondary Breast cancer Breast Neoplasms - blood Breast Neoplasms - diagnosis Breast Neoplasms - mortality Case-Control Studies Disease Progression Female Hedgehog protein Hedgehog Proteins - blood Humanities and Social Sciences Humans Immunoassays Interleukin 6 Interleukin-6 - blood Lymph nodes Metastases Metastasis multidisciplinary Neoplasm Metastasis Neoplasm Staging Prognosis ROC Curve Science Science (multidisciplinary) Serum levels Statistical analysis Survival Whole Body Imaging
ISSN:	2045-2322, 2045-2322
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Serum from one hundred and ten breast cancer patients and thirty healthy female volunteers, were prospectively collected and evaluated for serum levels of Shh and IL-6 using human Shh and IL-6 specific enzyme-linked immunoassays. All patients were regularly monitored for event free survival (EFS) and overall survival (OS). Overall outcome analysis was based on serum Shh and IL-6 levels. In patients with progressive metastatic BC, both serum Shh and IL-6 concentrations were elevated in 44% (29 of 65) and 63% (41 of 65) of patients, respectively, at a statistically significant level [Shh (p = 0.0001) and IL-6 (p = 0.0001)] compared to the low levels in healthy volunteers. Serum levels tended to increase with metastatic progression and lymph node positivity. High serum Shh and IL-6 levels were associated with poor EFS and OS opposite to the negative or lower levels in serum Shh and IL-6. The elevated levels of both serum Shh and IL-6 were mainly observed in BC patients who had a significantly higher risk of early recurrence and bone metastasis, and associated with a worse survival for patients with progressive metastatic BC. Further studies are warranted for validating these biomarkers as prognostic tools in a larger patient cohort and in a longer follow-up study.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	2045-2322 2045-2322
DOI:	10.1038/s41598-017-01268-4